REGENXBIO (RGNX)
(Delayed Data from NSDQ)
$16.19 USD
+0.13 (0.81%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $16.19 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$16.19 USD
+0.13 (0.81%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $16.19 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Zacks News
Implied Volatility Surging for REGENXBIO (RGNX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to REGENXBIO (RGNX) stock based on the movements in the options market lately.
ALXN vs. RGNX: Which Stock Is the Better Value Option?
by Zacks Equity Research
ALXN vs. RGNX: Which Stock Is the Better Value Option?
ALXN or RGNX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ALXN vs. RGNX: Which Stock Is the Better Value Option?
ALXN vs. RGNX: Which Stock Is the Better Value Option?
by Zacks Equity Research
ALXN vs. RGNX: Which Stock Is the Better Value Option?
5 Top Performing Stocks of the Best ETF of 1H2018
by Sweta Killa
Inside the top performing stocks of the top ETF of the first half of 2018.
ALXN vs. RGNX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ALXN vs. RGNX: Which Stock Is the Better Value Option?
REGENXBIO (RGNX) in Focus: Stock Moves 6.2% Higher
by Zacks Equity Research
REGENXBIO (RGNX) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Puma (PBYI) Q3 Earnings: Will it Surpass Estimates Again?
by Zacks Equity Research
Puma Biotechnology's (PBYI) only marketed product, Nerlynx (neratinib), for advanced breast cancer was launched in August. So Q3 is the first quarter in which Puma will record sales for Nerlynx.
BioDelivery (BDSI) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
BioDelivery Sciences (BDSI) has been focusing on growth territories and expanding Bunavail's label. However, the extent to which these impact third-quarter results remains to be seen.
What's in the Cards for Merrimack (MACK) in Q3 Earnings?
by Zacks Equity Research
Merrimack Pharmaceuticals (MACK) will report its third-quarter results later this month. Investors focus is expected to be on pipeline updates.
What's in the Cards for Repros (RPRX) This Earnings Season?
by Zacks Equity Research
Repros Therapeutics (RPRX) will report its third-quarter results later this month. Investors focus is expected to be on pipeline updates.
Regenxbio (RGNX) in Focus: Stock Moves 9.5% Higher
by Zacks Equity Research
Regenxbio (RGNX) was a big mover last session, as the company saw its shares rise more than 9% on the day.